Clinical Policy: Gemcitabine Intravesical System (Inlexzo)
Customize your policy alerts
Sign up for mhn Policy CP.PHAR.753 alerts
Get alerted when Policy CP.PHAR.753 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity and prior authorization criteria for Inlexzo (gemcitabine intravesical system) for treatment of BCG-unresponsive non-muscle invasive bladder cancer and related coverage rules for affected members and providers.
Provider attestation that Adstiladrin® therapy has been considered and not recommended (provider must submit clinical rationale supporting use of Inlexzo over Adstiladrin) is required.
HCPCS code J9183 (Gemcitabine intravesical system, 225 mg) was added and codes J3590 and C9399 were removed.
ICHRA (health insurance marketplace/ICHRA) line of business was added to the policy.
Coverage Criteria
Initial Therapy
Covered when ALL of the following are met:
Approval duration: 12 months
Continuation Therapy
Covered when ALL of the following are met:
Approval duration: 12 months
Other Indications / Off-label Handling
If use is not listed under covered indications:
See related policies CP.CPA.190, HIM.PA.103/HIM.PA.154, CP.PMN.16/CP.PMN.53 for details
Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation demonstrating efficacy and safety in accordance with the applicable off‑label use policy. Applicable off‑label policies include CP.CPA.09 (commercial), HIM.PA.154 (health insurance marketplace/ICHRA), and CP.PMN.53 (Medicaid), or other evidence of coverage documents as applicable.
When state Medicaid coverage provisions conflict with the requirements or coverage provisions in this clinical policy, the state Medicaid provisions take precedence. Providers should consult the applicable state Medicaid manual for any state‑specific coverage rules that apply to Medicaid members.
Requests for diagnoses or indications that are non‑FDA approved and that lack sufficient documentation of efficacy and safety per the applicable off‑label use policies are considered not authorized and may be denied. Providers must follow the referenced off‑label policies (for the member's line of business) and submit supporting clinical evidence when requesting coverage for off‑label use.
Coding and Billing
| J9183 | Gemcitabine intravesical system, 225 mg |
Provider Actions and Documentation Requirements
Prior authorization required — 12‑month approvals
Prior authorization is required for Inlexzo (J9183); when the approval criteria for initial or continued therapy are met, authorization is granted for 12 months.
Use J9183 for Inlexzo and follow PA process
Use HCPCS code J9183 (Gemcitabine intravesical system, 225 mg) when requesting coverage for Inlexzo and follow the Health Plan’s prior authorization processes for this code; include any required attestation about consideration of Adstiladrin when submitting the request.
BCG step — refractory requirement
Prior authorization for BCG immunotherapy may be required; member must be refractory to BCG as defined in Appendix D (BCG‑unresponsive) to meet initial therapy criteria.
- BCG prior authorization may be required
- Member must meet the policy definition of BCG‑unresponsive per Appendix D
Document consideration of Adstiladrin
Document in the prior authorization request that alternative intravesical therapy Adstiladrin was considered and not recommended; include clinical rationale explaining why Adstiladrin is not appropriate and Inlexzo is being requested instead.
Submit supportive clinical documentation
Submit clinical documentation (such as office chart notes, lab results, TURBT records, and other relevant clinical information) demonstrating the member meets all approval criteria for Inlexzo.
- Evidence of prior TURBT and BCG‑refractory status
- Clinical notes showing indication (NMIBC with CIS) and prescriber specialty
- Objective evidence of response for continuation requests
Attestation: Adstiladrin considered and not recommended
Include a signed provider attestation that Adstiladrin® therapy has been considered and not recommended, and provide the clinical rationale supporting use of Inlexzo over Adstiladrin as part of the prior authorization submission.
Include required documentation and attestation with J9183 requests
When requesting coverage for J9183, submit documentation supporting medical necessity for the Gemcitabine intravesical system and include the required provider attestation regarding Adstiladrin consideration per the policy revisions.
- Clinical evidence supporting dosing and prior treatments
- Provider attestation addressing Adstiladrin consideration and rationale
Denial risk for non‑FDA approved indications without adequate evidence
Requests for non‑FDA approved (off‑label) indications that lack sufficient documentation of efficacy and safety per the applicable off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) may be denied.
- If the use is not listed under the policy, follow the referenced off‑label use policy for the applicable line of business
Coding inclusion/exclusion does not guarantee coverage
Inclusion or exclusion of codes in this policy does not guarantee coverage; providers must reference the most up‑to‑date professional coding guidance prior to claim submission.
Background
Inlexzo (gemcitabine intravesical system) is an intravesical formulation of gemcitabine indicated for adult patients with BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The product is intended for intravesical instillation per the prescribing information; use for indications not within the FDA‑approved labeling requires off‑label documentation per the applicable off‑label policies.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.